A recent randomized double-blind placebo-controlled clinical trial (the CANTOS trial) showed that antiinflammatory therapy with an IL-1β–specific antibody (canakinumab) substantially reduced cardiovascular events (68), supporting our conclusion that IL-1β is a key signaling component in DM-associated cardiovascular complications. This evidence concerns the gene IL1B and diabetes mellitus.